|New Century Pharmaceuticals, Inc. is a biopharmaceutical company with an Oncology and Anti-infective focus which uses leading expertise in albumin structure and chemistry to improve drug safety and efficacy. NCP is currently advancing a number of important oncology product candidates through preclinical studies and commercializing through out-licensing and partnerships.
- October 2011, New Century licenses magnetic properties of its Ferrigen platform to Integrated Magnetic Systems in Dundee, Scotland. Read More »
- 2010 New Century published overview of its CADEX albumin structural survey as an invited chapter in Burger’s Drug Design and Development: D.C. Carter, “Crystallographic Survey of Albumin Drug Interaction and Applications in Cancer Chemotherapy,” Burger’s Drug Design and Development, 7th Edition, John Wiley & Sons; 437-468 (2010).
- December 2010, F-star licenses therapeutic applications with Boehringer Ingelheim. Read More »
- May 2009, New Century licenses its recombinant product portfolio to Albumin Therapeutics. Read More »